A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
To compare, in patients with advanced pancreatic cancer, the effects of IMM-101 in
combination with gemcitabine to gemcitabine alone on safety and tolerability (including QoL),
clinical signs and symptoms of disease, selected markers of tumour burden and immunological
status, and disease outcome.